International Stem Cell Corp (PK:ISCO)

Business Focus: Biotechnology & Medical Research

May 17, 2022 06:00 am ET
International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022
SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022.
Mar 30, 2022 09:15 am ET
International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results
SAN DIEGO, CA / ACCESSWIRE / March 30, 2022 / International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2021.
Nov 18, 2021 02:04 pm ET
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the...
Jun 30, 2021 08:57 am ET
International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease
CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today successful completion of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment of Pa
Nov 15, 2019 09:00 pm ET
International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019
CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019.
May 17, 2019 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
May 08, 2019 08:30 am ET
International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research
International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $43...
Apr 29, 2019 08:30 am ET
International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial
International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the...
Apr 15, 2019 08:30 am ET
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results
International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced...
Mar 04, 2019 07:00 am ET
International Stem Cell Corporation Commences Trading on the OTCQX Best Market
International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Mar 04, 2019 06:00 am ET
OTC Markets Group Welcomes International Stem Cell Corporation to OTCQX
NEW YORK, March 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced International Stem Cell Corporation (OTCQX: ISCO), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, has qualified to trade on the OTCQX® Best Market. International Stem Cell Corporation upgraded to OTCQX from the OTCQB® Venture Market.
Feb 13, 2019 08:30 am ET
International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Jan 15, 2019 08:30 am ET
International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced...
Dec 04, 2018 07:48 am ET
Edison issues update on International Stem Cell (ISCO)
International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of $2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the...
Nov 15, 2018 08:30 am ET
International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
Nov 05, 2018 08:30 am ET
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
via NetworkWire – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products,...
Nov 05, 2018 08:30 am ET
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today...
Oct 30, 2018 08:30 am ET
International Stem Cell Corporation to Present Clinical Data at the Society for Neuroscience Annual Meeting
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today it...
Oct 08, 2018 08:30 am ET
International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that...
Oct 02, 2018 08:00 am ET
International Stem Cell Corporation Raised Funds Through a Private Placement at Premium to Market
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Aug 21, 2018 07:00 am ET
International Stem Cell Corporation Granted Key US Patent Protecting Lead Therapeutic Program
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Aug 15, 2018 07:00 am ET
International Stem Cell Corporation Announces Record Sales and Operating Results for the Three and Six-Months ended June 30, 2018
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
Aug 06, 2018 07:00 am ET
International Stem Cell Corporation Developed 3D Liver Structures
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Jul 10, 2018 07:00 am ET
International Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical Products
International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly owned...
Jun 25, 2018 07:00 am ET
International Stem Cell Corporation Publishes Advanced Stem Cell Therapy Methodology in Stem Cells and Development Journal
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
Jun 11, 2018 07:00 am ET
International Stem Cell Corporation Doses First Patient of the Third Cohort in Parkinson's Disease Clinical Trial
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that...
Jun 05, 2018 07:00 am ET
International Stem Cell Corporation to Launch Advanced Joint Supplement
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
May 30, 2018 07:00 am ET
International Stem Cell Corporation Published Technology for Cartilage Generation in Journal of Tissue Engineering and Regenerative Medicine Technology
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today...
May 22, 2018 07:00 am ET
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2018
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
May 14, 2018 08:30 am ET
International Stem Cell Corporation is Valued at $34 Million Market Value by Edison Investment Research
International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $34...
May 07, 2018 08:30 am ET
International Stem Cell Corporation Granted Key Patent in US
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the United...
Apr 18, 2018 08:30 am ET
International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
CARLSBAD, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its...
Apr 10, 2018 08:45 am ET
International Stem Cell Corporation Announces 2017 Fourth Quarter and Year-End Results
CARLSBAD, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
Apr 10, 2018 08:30 am ET
International Stem Cell Corporation Announces 2017 Fourth Quarter and Year-End Results
CARLSBAD, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and...
Mar 05, 2018 08:30 am ET
International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson's Disease Clinical Trial
CARLSBAD, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the eighth participant, which completes the dosing of the...
Jan 22, 2018 08:30 am ET
International Stem Cell Corporation is Valued at $33 Million Market Value by Edison Investment Research
CARLSBAD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued...
Jan 11, 2018 08:45 am ET
International Stem Cell Corporation Treated Real Estate Icon Kevin Weeks
CARLSBAD, Calif., Jan. 11, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported...
Jan 11, 2018 08:45 am ET
International Stem Cell Corporation Treated Real Estate Icon Kevin Weeks
CARLSBAD, Calif., Jan. 11, 2018 (GLOBE NEWSWIRE) -- via Network NewsWire – International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported today...
Nov 29, 2017 08:30 am ET
International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease
CARLSBAD, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported today that a third patient...
Nov 29, 2017 08:30 am ET
International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease
CARLSBAD, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported today that a third patient...
Nov 17, 2017 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017
CARLSBAD, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and...
Nov 13, 2017 08:30 am ET
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial
CARLSBAD, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim results of the first cohort...
Nov 13, 2017 08:30 am ET
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial
International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim results of the first cohort of Parkinson's disease (PD) patients receiving 30 million ISC-hpNSC cells in the ongoing clinical study. All patients in the first cohort are currently meeting the primary endpoint, which is safety.
Nov 08, 2017 08:30 am ET
International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson's Disease at Neuroscience 2017
CARLSBAD, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its Executive Vice President and Chief Scientific Officer, Russell...
Oct 31, 2017 09:00 am ET
International Stem Cell Corporation Receives Key Stem Cell Patent in Australia
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based clinical stage biotechnology company that develops novel stem cell-based therapies and biomedical products, today announces ISCO's patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs has been issued in Australia. This new development significantly strengths ISCO's intellectual property position and partnering ability in the Asia-Pacific region.
Oct 09, 2017 08:30 am ET
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company that develops novel stem cell-based therapies and biomedical products, announced today a significant advancement in 3D bioprinting of liver tissue.
Oct 09, 2017 08:30 am ET
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
CARLSBAD, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company that develops novel stem cell-based therapies and biomedical products, announced today a significant advancement in 3D bioprinting of liver tissue....
Aug 14, 2017 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Three and Six-Months ended June 30, 2017
CARLSBAD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and six months ended June 30, 2017....
May 09, 2017 08:30 am ET
International Stem Cell Corporation Receives Approval to Start Second Patient Cohort in Clinical Trial for Parkinson’s Disease
CARLSBAD, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that that the Data Safety Monitoring Board (DSMB), a group of experts monitoring the clinical trial of ISC-hpNSC® neural cells, has reviewed the safety data from the first cohort in the  clinical trial. The DSMB has authorized the clinical trial to move forward with accelerated enrollment and dose escalation to the second cohort. Recruitment for the second coho...
Dec 07, 2016 08:30 am ET
International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
CARLSBAD, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced the treatment of the second patient in the Australian trial for Parkinson’s Disease. The patient was injected with 30,000,000 ISC-hpNSC® cells and is currently recovering....
Nov 16, 2016 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Three and Nine-months ended September 30, 2016
CARLSBAD, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2016....
Oct 18, 2016 08:30 am ET
International Stem Cell Corporation Announces Positive Efficacy Results in Traumatic Brain Injury
CARLSBAD, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the company's proprietary ISC-hpNSC® readily expandable neural stem cells improved cognitive performance and motor coordination in rodents with traumatic brain injury. The study was conducted by Distinguished Professor Cesar Borlongan, Vice-Chairman for Research Department of Neurosurgery and Brain Repair and Director of Center of Excellence for Aging a...
Sep 07, 2016 08:30 am ET
International Stem Cell Corporation to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
CARLSBAD, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present at the 18th Annual Rodman & Renshaw Global Investment Conference....
Aug 16, 2016 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Three and Six-Months Ended June 30, 2016
CARLSBAD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and six months ended June 30, 2016....
Jul 28, 2016 08:30 am ET
International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
CARLSBAD, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson’s Disease (PD). The operation took place at The Royal Melbourne Hospital in Australia....
Jun 02, 2016 08:30 am ET
International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical,...
May 23, 2016 09:00 am ET
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
IRVINE, Calif., May 23, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO") for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
May 17, 2016 08:30 am ET
International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
Mar 31, 2016 08:30 am ET
International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a...
Mar 10, 2016 08:30 am ET
International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products , announced today it has entered into definitive agreements with two institutional...
Mar 07, 2016 08:30 am ET
International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it is enrolling patients in the Phase I trial of ISC-hpNSC®, human parthenogenetic stem...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.